1	TITLE
2	Beta-blocker exposure is associated with nonunion in a geriatric cohort of 253,266
3	extremity fractures
4	AUTHORS
5	Lillia Steffenson <sup>1</sup> , Brook Martin <sup>1</sup> , Adam Kantor <sup>1</sup> , Dillon O'Neill <sup>1</sup> , Luke Myhre <sup>1</sup> , Tyler
6	Thorne <sup>1</sup> , David Rothberg <sup>1</sup> , Thomas Higgins <sup>1</sup> , Justin Haller <sup>1</sup> , Lucas Marchand <sup>1</sup>
7	AFFILIATIONS
8	1. University of Utah
9	CORRESPONDING AUTHOR
10	Lillia Steffenson, MD
11	Department of Orthopaedics
12	University of Utah School of Medicine
13	590 Wakara Way
14	Salt Lake City, UT 84108
15	Phone: (801) 587-7100
16	Fax: 801-587-5411
17	E-mail: Lillia.Steffenson@hsc.utah.edu
18	
19	Conflict of Interest: The authors have declared that no conflict of interest exists.
20	

## 21 ABSTRACT

Previously published animal studies have shown positive skeletal effects with local or 22 systemic administration of beta blockers (BBs). However, population studies have 23 shown mixed effects on bone mineral density (BMD) and fracture risk with BB use. The 24 goal of this study was to evaluate whether exposure to BB is associated with fracture 25 nonunion. Fee-for-service Medicare beneficiaries with an extremity fracture were 26 identified by International Classification of Diseases (ICD)-10 and current procedural 27 terminology (CPT) codes from 2016-2019. Charlson Comorbidity Index (CCI) was 28 assigned using diagnoses prior to index fracture and nonunion identified by ICD-10 or 29 CPT codes within one year from index fracture diagnosis. Patients were classified by 30 BB exposure based on Part D (Pharmacy) claims between 90 days prior to and one 31 year following index fracture. Chi square and Student's T-tests were performed on 32 categorical and continuous variables, respectively. Logistic regression was performed to 33 evaluate the association between BB use and nonunion, controlling for age, sex, race, 34 and comorbidity. Total number of fractures meeting inclusion criteria was 253,266 with 35 45% of patients having used a BB during the study period. The incidence of nonunion 36 was 3.9% overall. BBs were associated with a 13% increase in non-union for all fracture 37 types, after controlling for age, sex, fracture location, and CCI (OR 1.13 [CI 1.06-1.20], 38 p<.001). Results of this study suggest a negative influence of BB on bone healing, 39 40 contrary to results of previously published animal models and epidemiologic observations, and demonstrate that BB use during fracture care is associated with 41 significant increase in incidence of nonunion. 42

43

### 44 INTRODUCTION

Beta blockers are a class of medications which act as antagonists to beta-adrenergic 45 receptors of the sympathetic nervous system (SNS). These receptors are found 46 47 primarily in mesenchymal tissue types including cardiac, pulmonary, and vascular smooth muscle as well as skeletal muscle, adipose and osseous tissue. There are three 48 subtypes of this adrenergic stimulated G-protein coupled receptor, beta-1, beta-2, and 49 beta-3 receptor, and effects vary due to the distribution of these receptors in different 50 tissues. Beta-1 receptors found within the heart increase heart rate and contractility 51 52 causing a rise in cardiac output while those in the kidneys promote renin secretion. When stimulated, beta-2 receptors result in bronchodilation, vasodilation, and enhanced 53 skeletal muscle contraction in addition to gluconeogenesis and insulin secretion. Beta-3 54 receptors within fat tissue increases lipolysis and relaxation of bladder smooth muscle. 55 56

57 Skeletal homeostasis is maintained by the constant balance of activity between osteoblasts (bone forming cells) and osteoclast (bone resorbing cells). This mechanism 58 may alter bone mineral density due to changes in activity or underlying physiologic 59 60 demands (1, 2). Within osseous tissue, beta-2 adrenergic receptors ( $\beta$ 2AR s) are found on both osteoblasts and osteoclasts where  $\beta 2AR$  activation by norepinephrine and 61 epinephrine induces bone loss through RANK ligand-mediated activation of osteoclasts 62 63 and inhibits osteoblast proliferation (3). In mice, deletion of adrenergic beta-2 receptor (Adrb2) leads to greater trabecular bone microarchitecture and bone mass within both 64 femur and vertebrae. Addition of beta-1 receptor knockout to the model results in loss 65

of this phenotype and overall decreased total bone volume and cortical thickness (4)
 suggesting differential effects of these two receptor subtypes.

68

Observational studies in humans have similarly identified that individuals taking beta 69 70 blocker medications have higher bone mineral density (BMD) and lower fracture risk (5-71 13). Considering post-menopausal women have been found to have higher sympathetic activity compared to pre-menopausal women and sympathetic nerve activity is inversely 72 correlated with trabecular bone volume (14), these findings have renewed interest in 73 74 modulating adrenergic signaling as a potential intervention for primary osteoporosis prevention (2). One such study by Khosla et al., saw increases in distal radius BMD in 75 76 post-menopausal women treated with 20 weeks of atenolol (15).

77

At present, there are no human studies evaluating the effect of beta blockers on fracture 78 outcome. However, in a murine fracture model, low dose propranolol over 9 weeks 79 increased periosteal and endosteal bone formation and improved consolidation of 80 fracture callus. In the absence of fracture, torsional strength of rat femurs was increased 81 82 by 33% with propranolol (16). In another study, intraperitoneal administration of the cardio selective BB nebivolol, had a dose dependent increase in histologic osseous 83 healing in rat femur fractures stabilized with intramedullary Kirschner wires, whereas 84 85 cartilage formation was greater in the control group (17). However, rat osteotomy healing with intraperitoneal propranolol administration in a third study did not change 86 final torsional strength or union rates, despite a nonsignificant increase in callus 87 88 strength at 5 weeks in the propranolol group (18).

89

The purpose of the present study was to evaluate the association between beta blocker
exposure and fracture healing in humans, given the evidence for anabolic osseous
effect in prior observational and animal studies.

- 93
- 94 METHODS
- 95 Study Cohort

A retrospective analysis of a convenience cohort drawn from Medicare beneficiaries 96 with a Part B (provider service) claim for back pain and/or osteoporosis from 2016-2019 97 was performed. Patients were included if they were over 65 years of age and had a Part 98 B inpatient or outpatient claim for a femur, tibia/fibula, forearm, or humerus fracture 99 identified by International Classification of Diseases and 10<sup>th</sup> Revision (ICD-10) codes 100 and Current Procedural Terminology codes (CPT) (Supplemental Table 1). From this 101 initial cohort, patients were then excluded if they were less than 65 years old at the time 102 103 of fracture, had Medicare through either the end stage renal disease (ESRD) or Social Security Disability Insurance (SSDI) entitlement programs, were not enrolled in 104 Medicare Part D coverage, had follow-up of less than 1 year (e.g. fracture occurred in 105 2019), died within a year of fracture, had a concurrent or prior diagnosis of nonunion by 106 ICD-10 codes at the time of index fracture, or had insufficient 1 year claims history prior 107 108 to fracture to calculate comorbidity index. The cohort was screened for duplicate claims which were excluded from final analysis. Patient demographics including age, sex, race 109 (simplified grouping as "White", "Black", or "Other"), and Charlson Comorbidity Index 110 111 (CCI) (19) were collected.

112

The primary outcome of this study was fracture status one year following index injury, dichotomized as union or non-union. Non-union was identified in the final cohort using CPT codes for nonunion and ICD-10 codes (Supplemental Table 1). A union of the fracture was assumed if the beneficiary claims history did not include a non-union diagnosis.

118

The analytical cohort was grouped based on exposure to beta blockers (supplemental 119 table 2) and statin medications for comparison and categorized as pre-fracture use only, 120 post-fracture use only, or both pre- and post-fracture exposure. Pre-fracture exposure 121 was defined as a prescription claim within 90 days prior to index fracture. Subgroup 122 123 analyses were also performed to evaluate differences in immediate post-fracture exposure within 90 days of index fracture, difference in non-union within each specific 124 type of fracture, between selective vs. non-selective beta blockers, then beta blockers 125 126 were combined with statins, and based number of beta blocker (statin) prescriptions filled served as a proxy for an exposure "dose-response", 127

128

129 Statistical Analysis

Descriptive statistics were presented for patient demographics, fracture types, rates of union and non-union, and medication use. Chi square and Student's T-tests were performed on categorical and continuous variables, respectively. Separate multivariable logistic regression models with robust standard errors were then used to describe the association between each medication class and fracture status at 1-year, both overall

135 and within each fracture type, controlling for age, sex, race and CCI. Similar logistic regression models were used to examine the relationship between medication timing 136 and non-union while controlling for age, sex, race, CCI, and fracture type. Analyses 137 138 were conducted using Stata 17.0 MP (College Station, TX) accessed through Medicare's Virtual Research Data Center, and presented as odds ratios with 139 hypotheses based on an alpha level of 0.001. A power analysis performed using a t 140 beta value of 0.80 indicated at least 5300 patients needed in each group to detect a 1% 141 142 difference in nonunion. 143 RESULTS 144 Starting with 1,079,157 extremity fractures, a total of 253,266 fractures met inclusion 145 146 criteria (Figure 1) with 85,114 femur fractures, 73,444 forearm fractures, 41,097 147 humerus fractures and 53,373 tibia or fibula fracture. Overall incidence of nonunion was 3.9%. The highest incidence of nonunion was observed among humerus fractures at 148 149 6.2%. Examining patient demographics, those diagnosed with nonunion were younger by an average of 2 years (p<.001) and there was a higher proportion of males (21.3%) 150 vs 17.8%, p<.001) (Table 2). There were no significant differences in race or CCI by 151 152 fracture outcome. 153

Exposure to beta blockers and statins was greater in males, patients with higher CCI,and black race (Table 3).

156

157	After controlling for age, sex, race, comorbidity, and fracture type, the multivariable
158	model did not reveal a significant association between statin use and nonunion (OR
159	1.05 [95%CI 1.01 – 1.47] p-value=0.018). However, beta blockers were associated with
160	an 11% increase in nonunion diagnosis (OR 1.11 [95%CI 1.06-1.15] <0.001) regardless
161	of the number of prescriptions in the follow up period (Table 4). When excluding those
162	taking statins, the increase of nonunion among beta blocker users was 13% (OR 1.13
163	[95% CI 1.06-1.20]).

164

165 Subgroup analysis:

There was no obvious pattern in the likelihood of non-union based on the timing of beta-166 blocker use relative to when the fracture occurred (Table 4). There was no difference 167 168 between selective (OR 1.12 [95%Cl 1.07 - 1.17]), non-selective (OR 1.15 [95%Cl 1.07 - 1.23]) or combined selective and non-selective (OR 1.15 [95%CI 0.99 - 1.34] BB 169 exposure on fracture status at 1 year (Table 5). All three categories had a higher risk 170 171 compared to the non-user group. Combined exposure of beta blocker and statin use had a modest increase in nonunion (OR 1.19 [1.12-1.25 p<0.001] compared to non-172 users but was not significantly more than taking either beta-blockers or stains alone 173 174 (Table 5). Neither a greater number of beta blockers prescription nor statin prescriptions filled was associated with a greater likelihood of non-union (Table 4). 175

176

177 Sensitivity analysis for unobserved confounding:

178 We performed a sensitivity analysis to explore the possibility for unobserved

179 confounders to account for the higher risk of non-union found among beta-blocker users

180 at 1 year. By definition, a confounder is a factor associated with both the exposure (beta blocker use) and the outcome (fracture non-union). A confounder sensitivity 181 analysis reports the magnitude that these associations require in order to nullify the 182 association that we observed. In our analysis, we found that a hypothetical unobserved 183 factor with an OR of 1.46 [or a lower CI limit of 1.31] for an association with both the 184 exposure and outcome was required to render our findings for beta blockers null. As 185 shown in Figure 2, a lesser association with the exposure requires an exponentially 186 greater association with the outcome (and vice versa). 187

188

### 189 DISCUSSION

Age-related bone loss is multi-factorial. The primary mechanism in both men and 190 191 women is gonadal sex steroid deficiency (20). While this change is more pronounced in post-menopausal women, men also experience age related declines in bone density 192 (21, 22). In women this can be attenuated by hormone replacement therapy (HRT) (23-193 194 25), due to HRT stimulation of growth hormone, TGFB and IGF-1 production (26-28). Use of HRT to treat osteopenia or osteoporosis, however, is associated with increased 195 risk of cardiovascular events and breast cancer and is not recommended as first line 196 therapy (21). Geriatric patients also have increased sympathetic nervous system 197 activity, contributing to the higher risk of multi organ system pathophysiologic changes 198 199 with aging (29, 30) as well as age-related bone loss (14).

200

201 Multiple epidemiologic studies from 2000-2015 identified that patients taking BBs have

higher BMD and lower fracture risk (5-13). Preceding data from murine models also

203 found an anabolic effect of beta blockers on bone, with osteotomized rats exposed to BB having greater callus formation and improved biomechanics compared to controls 204 (16, 17). The proposed mechanism of this observation is antagonism of normal skeletal 205 B2AR function in stimulating osteoclasts (31). While some animal studies similarly 206 found positive effects of beta blockers on osteotomy healing, there is competing basic 207 science evidence for this association across rodent models (18, 32-35). The aim of this 208 study was to further evaluate the association between beta blockers and fracture 209 210 fracture healing in humans.

211

In the present study, there was a modest but significant increase in the diagnosis of 212 nonunion among patients taking beta blockers. There was no difference between 213 214 cardioselective and nonselective beta blocker exposure. This finding is supported by a previous database study, which also observed an association between cardiac 215 medications and diuretics and nonunion (36). The present study focused on beta 216 217 blocker use given the abundance of basic science research regarding the mechanism of action of beta blockers in modulating osseous physiology. Notably, the study by 218 Buccheit et al., did not detect higher incidence of nonunion with steroid medications or 219 220 immunosuppressant exposure following fracture treatment.

221

Our findings contradict the existing literature regarding the osseoanabolic effect of beta blockers and ongoing research regarding beta blockers as a potential primary preventative agent for osteopenia and osteoporosis (2). However, it is important to consider that adrenergic receptors have differential effects depending on the subtype 226 targeted by pharmacologic interventions. For example, the primary subtype expressed in bone is  $\beta$ 2AR, which when stimulated by glucocorticoids results in lower bone 227 density, while co-treatment with propranolol was protective against bone loss (37). On 228 229 the other hand, beta-1 receptor knockout mice at 4 months have lower BMD, lower bone volume, and trabecular volume when compared to both wild type (WT) and Adbr2 230 knockout mice (4), indicating that normal adrenergic beta-1 receptor function is 231 important for maintenance of bone volume and density in a murine model. Furthermore, 232 in the same study by Pierroz et al., Adbr1b2<sup>-/-</sup> mice had persistent decreases in whole 233 body BMD up to 40 and 50 weeks of age, but this difference diminished as the mice 234 approached 60 weeks of age. Based on these findings, the authors propose that beta 2 235 signaling is higher in bone of wild type mice, but beta-1 signaling may be just as 236 237 important in the regulation of skeletal tissue.

238

Additionally, one must consider the condition where SNS activation is known to improve 239 240 fracture healing. In moderate and severe traumatic brain injury (TBI), fracture healing is accelerated in both clinical studies and murine models (38-41). TBI results in several 241 pathophysiologic effects, but largely increases SNS activity. In an unpublished 242 independent study by Jahn et al., the authors found that increased NE-Arb2 signaling 243 mediates TBI-induced skeletal manifestations in both bone remodeling and 244 245 regeneration. Furthermore, the study demonstrates that Adrb2 plays an age-dependent and pharmacologically targetable role in fracture healing by promoting callus 246 vascularization under conditions of increased sympathetic tone. The beneficial effect of 247 248 TBI on bone regeneration was also completely absent in mice lacking Adrb2 (medRxiv

- BIORXIV/2023/548550). These findings suggest an essential function of Adrb2 in
- promoting bone repair and provide evidence that in a hyperadrenergic state, activity by
- these receptors may be essential for normal bone healing.
- 252
- The challenge in these large observational studies remains the difficulty in determining 253 the medication effect, versus a reflection of the patient's overall health status that is not 254 completely captured by comorbidity indices. The studies in question all use different 255 256 methods to control for comorbidities, which may confuse the results. It is also difficult to discern if route of medication administration and age of the specimens may change the 257 central and peripheral effects of these medications. Finally, the present study is limited 258 as it is a convenience cohort of Medicare patients is not generalizable to the general 259 260 population.
- 261

## 262 AUTHOR CONTRIBUTIONS

Authorship note: LS and BM collaborated on study design, LM supervised the study, BM performed statistical analysis, LS prepared the manuscript which was reviewed and edited by the remaining authors.

266

# 267 ACKNOWLEDEMENT

Funding support provided by internal grant from the LS Peery MD Discovery Program ofthe University of Utah's Department of Orthopaedics.

270

271

#### 272 **REFERENCES**

1. Takeda S, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell.

274 2002;111(3):305-317.

- Karsenty G, and Khosla S. The crosstalk between bone remodeling and energy metabolism: A
   translational perspective. Cell Metab. 2022;34(6):805-817.
- Elefteriou F, et al. Leptin regulation of bone resorption by the sympathetic nervous system and
   CART. Nature. 2005;434(7032):514-520.
- Pierroz DD, et al. Deletion of β-adrenergic receptor 1, 2, or both leads to different bone
   phenotypes and response to mechanical stimulation. J Bone Miner Res. 2012;27(6):1252-1262.
- 5. Schlienger RG, et al. Use of beta-blockers and risk of fractures. JAMA. 2004;292(11):1326-1332.
- Pasco JA, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone
   mineral density: Geelong Osteoporosis Study. J Bone Miner Res. 2004;19(1):19-24.
- L. Rejnmark, et al. Fracture risk in perimenopausal women treated with beta-blockers Calcif
   Tissue Int, 75 (2004), pp. 365-372
- Wiens M, et al. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis
   of observational studies. J Intern Med. 2006;260(4):350-362.
- Graham S, et al. The effect of beta-blockers on bone metabolism as potential drugs under
- investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs. 2008;17(9):12811299.
- 291 10. Yang S, et al Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis
   292 Epidemiology Study. Bone. 2011;48(3):451-455.
- 293 11. Yang S, et al. Association between beta-blockers and fracture risk: a Bayesian meta-analysis.
   294 Bone. 2012;51(5):969-974.
- Toulis KA, et al. β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of
   selectivity, gender, and site-specific effects. Osteoporos Int. 2014;25(1):121-129.
- 13. Schlienger RG, et al. Use of beta-blockers and risk of fractures. JAMA. 2004;292(11):1326-1332.
- 298 14. Farr JN, et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma
- osteopontin levels in women. J Clin Endocrinol Metab. 2012;97(11):4219-4227.

- 300 15. Khosla S, et al. Sympathetic β1-adrenergic signaling contributes to regulation of human bone
- 301 metabolism. J Clin Invest. 2018;128(11):4832-4842.
- 302 16. Minkowitz B, et al. Effects of propranolol on bone metabolism in the rat. J Orthop Res.
- 303 1991;9(6):869-875.
- 304 17. Metineren H, et al. Effect of nebivolol on fracture healing: An experimental rat model. Adv Clin
   305 Exp Med. 2017;26(6):919-923
- 306 18. Smitham P, et al. Low dose of propranolol does not affect rat osteotomy healing and callus
   307 strength. J Orthop Res. 2014;32(7):887-893.
- 308 19. Quan H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10
- 309 administrative data. Medical Care 2005. Nov; 43(11):1073-1077.
- 20. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol
   Metab Clin North Am. 2005 Dec;34(4):1015-30, xi.
- 312 21. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):441-464.
- 22. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95(1):3-10.
- 314 23. Tobias JH, Compston JE. Does estrogen stimulate osteoblast function in postmenopausal
  315 women?. Bone. 1999;24(2):121-124.
- 316 24. Lindsay R, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence
- for an increased bone mass after delayed onset of oestrogen treatment. Lancet.
- 318 1976;1(7968):1038–1041.
- 319 25. Genant HK, et al. Quantitative computed tomography of vertebral spongiosa: a sensitive method
   320 for detecting early bone loss after oophorectomy. Ann Intern Med. 1982;97(5):699–705.
- 321 26. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in
   322 experimental animals and the human. Endocr Rev. 1998;19(6):717-797.
- 323 27. Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for
- 324 collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase
- 325 activity in osteoblastic cells from calvariae and long bones. Endocrinology. 1989;125(2):825-833.

- 326 28. Oursler MJ, et al. Modulation of transforming growth factor-beta production in normal human
- 327 osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology.

328 1991;129(6):3313-3320.

- 329 29. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal
- 330 women: principal results From the Women's Health Initiative randomized controlled trial. JAMA.
- 331 2002;288(3):321-333.
- 332 30. Pfeifer MA, et al. Differential changes of autonomic nervous system function with age in man. Am
   333 J Med. 1983;75(2):249-258.
- 334 31. Jones PP, et al. Age-related increase in muscle sympathetic nerve activity is associated with
   abdominal adiposity. Am J Physiol. 1997;272(6 Pt 1):E976-E980.
- 336 32. Bonnet N, et al. Protective effect of beta blockers in postmenopausal women: influence on
- fractures, bone density, micro and macroarchitecture. Bone. 2007;40(5):1209-1216.
- 338 33. Suzuki A, et al. Catecholamines stimulate the proliferation and alkaline phosphatase activity of
   339 MC3T3-E1 osteoblast-like cells. Bone 1998;23:197-203.
- 34. Zeman RJ, et al. Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated
  hindlimbs. Am J Physiol 1991;261:E285-9.
- 342 35. Pataki A, et al. Anabolic effects of beta2-agonists, formoterol and salbutamol on cancellous bone
  343 of ovariectomized rat. Bone 1996;9:A116.
- 36. Buchheit T, et al. Opioid exposure is associated with nonunion risk in a traumatically injured
   population: An inception cohort study. Injury. 2018;49(7):1266-1271.
- 346 37. Ma Y, et al. β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of
   347 glucocorticoids on bone. Endocrinology. 2011;152(4):1412-1422.
- 348 38. Perkins R, Skirving AP. Callus formation and the rate of healing of femoral fractures in patients
  with head injuries. J Bone Joint Surg Br. 1987;69(4):521-524. doi:10.1302/0301-
- 350 620X.69B4.3611150
- 35. Yang C, et al. The effect of traumatic brain injury on bone healing from a novel exosome centered
   perspective in a mice model. J Orthop Translat. 2021;30:70-81. Published 2021 Sep 23.


- 40. Bajwa NM, et al. Long-term Consequences of Traumatic Brain Injury in Bone Metabolism. Front
   Neurol. 2018;9:115. Published 2018 Mar 5.
- 41. Locher RJ, et al. Traumatic brain injury and bone healing: radiographic and biomechanical
- analyses of bone formation and stability in a combined murine trauma model. J Musculoskelet
- 357 Neuronal Interact. 2015;15(4):309-315.
- 358

# 359 TABLE AND FIGURE LEGENDS

- Figure 1. Consort diagram of study cohort. Patients were excluded if they were eligible for
- 361 Medicare through social security disability (SSDI), end-stage renal disease (ESRD)
- 362 entitlements, had insufficient Part D pharmacy data or at least 1 year of claims data.
- 363
- Table 1: Fracture union status at 1-year, within fracture type cohort.
- 365
- Table 2: Demographic Characteristics between Medicare beneficiaries who did or did not
- 367 experience non-union within one year following fracture.
- 368
- Table 3. Demographic Characteristics between Medicare beneficiaries based on medication
   exposure.
- 371
- Table 4: Association of select medications on non-union, controlling for age, sex, race, Charlson
- 373 comorbidity index (365-day lookback), and fracture type. (Prescription = Rx)
- 374
- Table 5: Sub analysis of combined medication exposure and beta blocker class on non-union,
- 376 controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type.
- 377

- 378 Figure 2. Sensitivity analysis examining the relationship between potential unaccounted
- 379 confounders.

**Figure 1.** Consort diagram of study cohort. Patients were excluded if they were eligible for Medicare through social security disability (SSDI), end-stage renal disease (ESRD) entitlements, had insufficient Part D pharmacy data or at least 1 year of claims data.



Fracture Cohort	Union	Non union	Total
Femur	82,059 (96.4%)	3,055 (3.6%)	85.114
Forearm	73,444 (97.2%)	2,144 (2.8%)	75,588
Humerus	38,566 (93.8%)	2,531 (6.2%)	41,097
Fibula/Tibia	51,041 (95.6%)	2,332 (4.4%)	53,373

**Table 1.** Fracture union status at 1-year, within fracture type cohort.

 Table 2. Demographic Characteristics between Medicare beneficiaries who did or did not

experience non-union within one year following fracture.

	Fractu			
	Union	Non-union	Total	p-value
	(n=243,319)	(n=9,947)	(n=253,266)	
Age (mean)	79.4	77.3	79.3	<0.001
Female, %	82.2	77.7	82.0	<0.001
Race (3 groups), %				
White	91.6	91.6	91.6	0.407
Black	3.3	3.1	3.2	
Other	5.2	5.4	5.2	
Comorbidity 365-day lookback,				
%				
0	21.7	21.4	21.7	0.739
1	20.6	20.5	20.6	
2	57.8	58.1	57.8	
Medication use				
Beta blocker, %	45.0	47.3	45.1	<0.001
Statin, %	53.3	56.6	53.4	<0.001

**Table 3.** Demographic Characteristics between Medicare beneficiaries based on medication

exposure.

	Beta Blocker		p value	Statin		p value
	No	Yes	Value	No	Yes	Value
N	139,096	114,170		117,921	135,345	
Age, mean (sd)	78.6	80.2		79.9	78.9	
	(8.1)	(7.8)		(8.5)	(7.6)	
Female, %	83.1	80.7	p<.001	84.8	79.6	p<.001
Race (3 groups), %						
White	91.6	91.6		92.2	91	
Black	2.9	3.6		3	3.4	
Other	5.5	4.8	p<.001	4.8	5.5	p<.001
Comorbidity 365-day						
lookback, %						
0	27.8	14.2		27.8	16.3	
1	22.9	17.6		22.5	18.9	
2	49.2	68.2	p<.001	49.7	64.8	p<.001

**Table 4.** Association of select medications on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type. (Prescription = Rx)

Model	Factor	OR (95%Cl)	Rate	p- value
Non-union as a function of any exposure to medication within 1 year of fracture.	Beta- blocker	1.11 (1.06 – 1.15)	3.7 vs.3.4	<0.00 1
	Statin	1.05 (1.01 – 1.10)	3.6 vs 3.5	0.018
Non-union as a function of beta blocker prescriptions filled (dose response) conditional on beta blocker use	1-4 Rx	1.00 (ref)	4	
	5-6 Rx	0.96 (0.89 – 1.03)	3.8	0.258
	7+ Rx	0.93 (0.87 – 1.00)	3.7	0.045
Non-union as a function of statin prescriptions filled (dose response) conditional on statin use	1 -4 Rx	1.00 (ref)	4.1	
	5 Rx	0.88 (0.83 – 0.95)	3.6	0.001
Non-union as a function pre and post-fracture beta blocker use	None	1.00 (ref)	3.5	
	Pre fracture beta-blocker use only	1.15 (0.97 – 1.35)	4.0	0.110
	Post fracture beta-blocker use only	1.14 (1.07 – 1.22)	3.9	<0.00 1
	Pre and post fracture beta-blocker use	1.12 (1.07 – 1.17)	3.9	<0.00 1

Table 5. Sub analysis of combined medication exposure and beta blocker class on non-union,

controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type.

Model	Factor	OR (95%CI)	Rat e	p- value
Non-union as a function of interaction between beta-blocker use and statin use	None	1.00 (Ref)	3.4	
	Beta-blocker	1.13 (1.06 - 1.20)	3.8	<0.00 1
	Statin	1.08 (1.02 - 1.14)	3.6	0.009
	Beta-blocker & statin	1.19 (1.12 – 1.25)	3.9	<0.00 1
Non-union as a function of beta-blocker type (selective or non-selective), conditioned on use of beta blocker	Select beta- blocker	1.00 (Ref)	3.8	-
	Non-select beta- blocker	1.03 (0.96 - 1.11)	3.9	0.355
	Select & non- select beta- blocker	1.04 (0.89 - 1.21)	4	0.621

Figure 2. Sensitivity analysis examining the relationship between potential unaccounted confounders.

